Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Thu H. Truong"'
Autor:
Todd P. Knutson, Thu H. Truong, Shihong Ma, Nicholas J. Brady, Megan E. Sullivan, Ganesh Raj, Kathryn L. Schwertfeger, Carol A. Lange
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-24 (2017)
Abstract Background Estrogen and progesterone are potent breast mitogens. In addition to steroid hormones, multiple signaling pathways input to estrogen receptor (ER) and progesterone receptor (PR) actions via posttranslational events. Protein kinase
Externí odkaz:
https://doaj.org/article/d895c78320194bcb987c09b05cebf111
Autor:
Amy R Dwyer, Carlos Perez Kerkvliet, Thu H Truong, Kyla M Hagen, Raisa I Krutilina, Deanna N Parke, Robert H Oakley, Christopher Liddle, John A Cidlowski, Tiffany N Seagroves, Carol A Lange
Publikováno v:
Endocrinology.
Corticosteroids act on the glucocorticoid receptor (GR; NR3C1) to resolve inflammation and are routinely prescribed to breast cancer patients undergoing chemotherapy treatment to alleviate side effects. Triple negative breast cancers (TNBCs) account
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de70e0a8a180e0c1fdd967333273d4aa
https://doi.org/10.1210/endocr/bqad083
https://doi.org/10.1210/endocr/bqad083
Autor:
Julie H. Ostrander, Carol A. Lange, Kathryn L. Schwertfeger, Nicholas J. Brady, Brian J. Girard, Kyla M. Hagen, Nuri A. Temiz, Hsiangyu Hu, Thu H. Truong
Supplementary Western Blots and RNA expression for PELP1, Western blot controls for fractionation, Kaplan Meier plots, soft agar assay images, and ALDH flow cytometry plots.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03353a0344a5795c36d02217014fdb00
https://doi.org/10.1158/1541-7786.22512645
https://doi.org/10.1158/1541-7786.22512645
Autor:
Julie H. Ostrander, Carol A. Lange, Kathryn L. Schwertfeger, Nicholas J. Brady, Brian J. Girard, Kyla M. Hagen, Nuri A. Temiz, Hsiangyu Hu, Thu H. Truong
Supplementary Tables 1-5 containing gene lists and pathway analyses from Mass spectrometry and RNA-seq.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::793b0b79178d6470d91f9c94a65dd322
https://doi.org/10.1158/1541-7786.22512642
https://doi.org/10.1158/1541-7786.22512642
Autor:
Julie H. Ostrander, Carol A. Lange, Kathryn L. Schwertfeger, Nicholas J. Brady, Brian J. Girard, Kyla M. Hagen, Nuri A. Temiz, Hsiangyu Hu, Thu H. Truong
Proline, glutamic acid, leucine-rich protein 1 (PELP1) is overexpressed in approximately 80% of invasive breast tumors. PELP1 dynamically shuttles between the nucleus and cytoplasm, but is primarily nuclear in normal breast tissue. However, altered l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1676b71b17f07460147806608e113b0
https://doi.org/10.1158/1541-7786.c.6540303.v1
https://doi.org/10.1158/1541-7786.c.6540303.v1
Publikováno v:
Essays Biochem
The classification and treatment of breast cancer is largely defined by the expression of steroid hormone receptors (HRs), namely estrogen receptor (ER) and progesterone receptor (PR), and gene amplification/overexpression of human epidermal growth f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59875652c7046902d01802b73c553d69
https://doi.org/10.1042/ebc20200165
https://doi.org/10.1042/ebc20200165
Autor:
Elizabeth Benner, Emilio Cortes-Sanchez, Carol A. Lange, Carlos Perez Kerkvliet, Camila O. dos Santos, Thomas Pengo, Chieh Hsiang Yang, Katrin P. Guillen, Sucheta Telang, Thu H. Truong, Ying Wang, Nuri A. Temiz, Marygrace C. Trousdell, Bryan E. Welm, Kyla M. Hagen, Julie H. Ostrander
Publikováno v:
Oncogene
Recurrence of metastatic breast cancer stemming from acquired endocrine and chemotherapy resistance remains a health burden for women with luminal (ER+) breast cancer. Disseminated ER+ tumor cells can remain viable but quiescent for years to decades.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bae2e21515093f53742fda452dc60ac
http://europepmc.org/articles/PMC8238912
http://europepmc.org/articles/PMC8238912
Autor:
Carlos Perez Kerkvliet, Peter Kabos, Carol A. Sartorius, Carol A. Lange, Thu H. Truong, Amy R. Dwyer, Kiran V. Paul
Publikováno v:
British Journal of Cancer
Background Progesterone receptors (PR) are potent modifiers of endocrine responses. In aberrant signalling cancer contexts, phosphorylation events dramatically alter steroid hormone receptor action. Methods The transcriptomes of primary tumours and m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fcd2df74d2097bc2bd58104aad23e84
https://doi.org/10.1038/s41416-020-01094-y
https://doi.org/10.1038/s41416-020-01094-y
Publikováno v:
Cancer Research. 79:P6-20
Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer related death in women. Around 5–10% of cases are metastatic at diagnosis, and close to 30% of patients with early stage disease will relapse with metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc34d0cd5be93f2bbb161b499509739c
https://doi.org/10.1158/1538-7445.sabcs18-p6-20-13
https://doi.org/10.1158/1538-7445.sabcs18-p6-20-13
Publikováno v:
Endocrinology. 160:430-446
Progesterone receptors (PRs) are key modifiers of estrogen receptor (ER) target genes and drivers of luminal breast cancer progression. Total PR expression, rather than isoform-specific PR expression, is measured in breast tumors as an indicator of f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2825c0b26811d51d48bc281d3aa3d14b
https://doi.org/10.1210/en.2018-00990
https://doi.org/10.1210/en.2018-00990